PERRY GREGORY D
Insider CIK 1236371 · ACTC Director · NVIV Interim CFO · AEGR See Remarks · KALA Director · EBIO Chief Financial and Business · MRUS Chief Financial Officer & PFO, Director · FNCH Chief Financial Officer · NVLN See Remarks · IMGN Chief Financial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 372,924 | — | $0 | 0 | SEC↗ |
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 107,300 | — | $0 | 0 | SEC↗ |
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 100,000 | — | $0 | 0 | SEC↗ |
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 14,414 | — | $0 | 0 | SEC↗ |
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 16,604 | — | $0 | 0 | SEC↗ |
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 6,120 | — | $0 | 0 | SEC↗ |
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 8,631 | — | $0 | 0 | SEC↗ |
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 17,000 | — | $0 | 0 | SEC↗ |
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 5,650 | — | $0 | 0 | SEC↗ |
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 4,983 | — | $0 | 0 | SEC↗ |
| MRUS Merus N.V. | D To issuer deriv | 2025-12-12 | 2025-12-12 | 8,500 | — | $0 | 0 | SEC↗ |
| KALA KALA BIO, Inc. | A Award deriv | 2025-06-15 | 2025-06-17 | 5,450 | — | $0 | 5,450 | SEC↗ |
| KALA KALA BIO, Inc. | A Award | 2025-06-15 | 2025-06-17 | 2,450 | — | $0 | 13,344 | SEC↗ |
| MRUS Merus N.V. | A Award deriv | 2025-01-29 | 2025-01-31 | 100,000 | — | $0 | 100,000 | SEC↗ |
| KALA KALA BIO, Inc. | A Award deriv | 2024-06-11 | 2024-06-12 | 3,150 | — | $0 | 3,150 | SEC↗ |
| KALA KALA BIO, Inc. | A Award | 2024-06-11 | 2024-06-12 | 1,400 | — | $0 | 10,894 | SEC↗ |
| MRUS Merus N.V. | A Award deriv | 2024-05-07 | 2024-05-09 | 107,300 | — | $0 | 107,300 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | A Award deriv | 2023-06-22 | 2023-06-23 | 2,500 | — | $0 | 2,500 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | A Award deriv | 2023-06-22 | 2023-06-23 | 7,808 | — | $0 | 7,808 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | A Award | 2023-06-22 | 2023-06-23 | 1,100 | — | $0 | 9,494 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | A Award | 2023-06-22 | 2023-06-23 | 5,856 | — | $0 | 8,394 | SEC↗ |
| MRUS Merus N.V. | A Award deriv | 2023-06-14 | 2023-06-15 | 372,924 | — | $0 | 372,924 | SEC↗ |
| MRUS Merus N.V. | A Award deriv | 2023-06-08 | 2023-06-12 | 14,414 | — | $0 | 14,414 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | D To issuer deriv | 2023-05-31 | 2023-06-02 | 420 | — | $0 | 0 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | D To issuer deriv | 2023-05-31 | 2023-06-02 | 518 | — | $0 | 0 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | D To issuer deriv | 2023-05-31 | 2023-06-02 | 800 | — | $0 | 0 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | A Award | 2023-05-31 | 2023-06-02 | 1,738 | — | $0 | 2,538 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | A Award deriv | 2022-06-16 | 2022-06-17 | 40,000 | — | $0 | 40,000 | SEC↗ |
| MRUS Merus N.V. | A Award deriv | 2022-05-31 | 2022-06-02 | 16,604 | — | $0 | 16,604 | SEC↗ |
| FNCH Finch Therapeutics Group, | A Award deriv | 2022-02-25 | 2022-02-28 | 80,000 | — | $0 | 80,000 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | A Award | 2021-06-17 | 2021-06-21 | 20,000 | — | $0 | 40,000 | SEC↗ |
| MRUS Merus N.V. | A Award deriv | 2021-05-28 | 2021-06-02 | 6,120 | — | $0 | 6,120 | SEC↗ |
| FNCH Finch Therapeutics Group, | A Award deriv | 2021-03-18 | 2021-03-18 | 55,386 | — | $0 | 55,386 | SEC↗ |
| MRUS Merus N.V. | A Award deriv | 2020-06-30 | 2020-07-02 | 8,631 | — | $0 | 8,631 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | A Award | 2020-06-25 | 2020-06-29 | 20,000 | — | $0 | 20,000 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | A Award deriv | 2019-06-05 | 2019-06-07 | 21,000 | — | $0 | 21,000 | SEC↗ |
| KALA Kala Pharmaceuticals, Inc. | A Award deriv | 2018-02-28 | 2018-03-02 | 25,920 | — | $0 | 25,920 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise deriv | 2017-05-09 | 2017-05-11 | 2,393 | — | $0 | 4,786 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | F Tax w/h | 2017-05-09 | 2017-05-11 | 710 | $9.42 | $6.7K | 1,683 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | M Exercise | 2017-05-09 | 2017-05-11 | 2,393 | — | $0 | 2,393 | SEC↗ |
| NVLN NOVELION THERAPEUTICS INC. | A Award deriv | 2016-12-22 | 2016-12-27 | 166,020 | — | $0 | 166,020 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 40,000 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 200,000 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 35,000 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 200,000 | — | $0 | 0 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | D To issuer deriv | 2016-11-29 | 2016-11-30 | 69,000 | — | $0 | 0 | SEC↗ |
| NVLN QLT INC/BC | A Award deriv | 2016-11-29 | 2016-12-01 | 35,896 | — | $0 | 35,896 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | A Award deriv | 2016-05-09 | 2016-05-11 | 35,000 | — | $0 | 35,000 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | A Award deriv | 2016-05-09 | 2016-05-11 | 69,000 | — | $0 | 69,000 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | A Award deriv | 2016-02-12 | 2016-02-17 | 200,000 | — | $0 | 200,000 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 5,000 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 5,000 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 5,000 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 417 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 5,000 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 5,000 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | U Tender | 2016-02-10 | 2016-02-11 | 21,417 | $8.50 | $182.0K | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award deriv | 2016-01-04 | 2016-01-04 | 5,000 | — | $0 | 5,000 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award | 2015-12-31 | 2016-01-04 | 1,250 | — | $0 | 21,417 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award | 2015-09-30 | 2015-10-01 | 1,250 | — | $0 | 20,167 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | A Award deriv | 2015-08-04 | 2015-08-06 | 40,000 | — | $0 | 40,000 | SEC↗ |
| AEGR Aegerion Pharmaceuticals, | A Award deriv | 2015-08-03 | 2015-08-04 | 200,000 | — | $0 | 200,000 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award | 2015-06-30 | 2015-07-02 | 1,250 | — | $0 | 18,917 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award | 2015-03-31 | 2015-04-01 | 1,250 | — | $0 | 17,667 | SEC↗ |
| EBIO Eleven Biotherapeutics, In | A Award deriv | 2015-02-26 | 2015-02-27 | 57,500 | — | $0 | 203,248 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award deriv | 2015-01-02 | 2015-01-05 | 5,000 | — | $0 | 5,000 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award | 2014-12-31 | 2015-01-02 | 1,250 | — | $0 | 16,417 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2014-09-30 | 2014-10-01 | 1,250 | — | $0 | 15,167 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2014-06-30 | 2014-07-02 | 125,000 | — | $0 | 1,391,667 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2014-03-31 | 2014-04-02 | 125,000 | — | $0 | 1,266,667 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award deriv | 2014-01-02 | 2014-01-03 | 500,000 | — | $0 | 500,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2013-12-31 | 2014-01-03 | 125,000 | — | $0 | 1,141,667 | SEC↗ |
| NVIV INVIVO THERAPEUTICS HOLDIN | A Award | 2013-12-30 | 2014-01-02 | 22,374 | — | $0 | 22,374 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2013-09-30 | 2013-10-02 | 125,000 | — | $0 | 1,016,667 | SEC↗ |
| IMGN IMMUNOGEN INC | M Exercise deriv | 2013-09-10 | 2013-09-11 | 18,337 | $4.32 | $79.2K | 56,665 | SEC↗ |
| IMGN IMMUNOGEN INC | M Exercise | 2013-09-10 | 2013-09-11 | 18,337 | $4.32 | $79.2K | 18,337 | SEC↗ |
| IMGN IMMUNOGEN INC | S Sale | 2013-09-10 | 2013-09-11 | 18,337 | $17.82 | $326.8K | 0 | SEC↗ |
| IMGN IMMUNOGEN INC | A Award deriv | 2013-07-16 | 2013-07-17 | 110,000 | $19.02 | $2.09M | 110,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2013-06-28 | 2013-07-01 | 125,000 | — | $0 | 891,667 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2013-03-28 | 2013-04-01 | 125,000 | — | $0 | 766,667 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award deriv | 2013-01-02 | 2013-02-26 | 500,000 | — | $0 | 500,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2012-12-31 | 2013-01-04 | 125,000 | — | $0 | 641,667 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2012-09-28 | 2012-10-03 | 125,000 | — | $0 | 516,667 | SEC↗ |
| IMGN IMMUNOGEN INC | A Award deriv | 2012-07-20 | 2012-07-23 | 100,000 | $15.83 | $1.58M | 100,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2012-06-29 | 2012-07-09 | 125,000 | — | $0 | 391,667 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2012-03-30 | 2012-04-04 | 125,000 | — | $0 | 266,667 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award deriv | 2012-01-03 | 2012-08-09 | 500,000 | — | $0 | 500,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award deriv | 2011-12-02 | 2012-02-27 | 41,667 | — | $0 | 41,667 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2011-12-02 | 2012-02-27 | 141,667 | — | $0 | 141,667 | SEC↗ |